Moreadith Randall 4

What Happened

• Moreadith Randall, Chief Scientific Officer of Serina Therapeutics (SER), was granted a derivative award covering 69,000 shares on February 3, 2026. The Form 4 reports an acquisition at $0.00 (no cash paid) for a derivative instrument; no immediate market value is provided in the filing.
• This appears to be an option-style grant (the filing’s footnote refers to “the option” and a multi-year vesting schedule). Grants are compensation and do not equate to an open-market purchase of stock.

Key Details

• Transaction date: 2026-02-03; Report filed: 2026-02-17 (filed 14 days after the transaction; this is later than the standard two-business-day Form 4 rule).
• Amount: 69,000 shares (derivative award) reported at $0.00 acquisition price; total dollar value not disclosed.
• Vesting (from footnote): 12/48ths of the shares vest 12 months after the Vesting Commencement Date, then 1/48th vests each month thereafter until fully vested.
• Shares owned after the transaction: not specified in the Form 4.
• No indication of an immediate exercise or sale in this filing.

Context

• This was an equity compensation grant (derivative/option) rather than an open-market buy; such awards are common for executives and reflect compensation rather than a direct bullish signal from the insider.
• Because the award vests over time, the economic benefit to the insider depends on future vesting and any eventual exercise price or sale. The late filing delays public visibility into the grant.